However, in many instances, tumour-reactive CD8 T-cells are present in low frequency and/or lack the critical functionality to eradicate established tumours.1,2 Conceivably, most cancer immunotherapeutic strategies focus on unleashing tumour-reactive CD8 T-cell responses capable of recognising and destroying tumour cells. This evidence concerns the gene CD8A and cancer.